Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 31, 2024
Event: Entry into an Accelerated Share Repurchase (ASR) agreement.
Key Financial Metrics
This filing reports a specific capital allocation event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow).
- Repurchase Authorization: $300.00 million total program.
- ASR Transaction Value: $300.00 million (Repurchase Price).
- Initial Share Delivery: 80% of the Repurchase Price value, based on the closing share price on October 31, 2024.
- Payment Date: November 4, 2024.
- Counterparty: Goldman Sachs & Co. LLC.
Material Changes
The Company has executed a significant portion of its previously announced share repurchase program through a single accelerated transaction. The filing does not provide comparative financial data against prior periods as it is a current event report.
Outlook, Risks, and Unusual Items
Transaction Mechanics: The final number of shares repurchased will be determined by the volume-weighted average price of the Common Stock during the term of the ASR, less a discount. The transaction is scheduled to terminate in the first quarter of 2025.
Settlement Contingencies: Upon final settlement, the Company may receive additional shares from Goldman Sachs or, under certain circumstances, may be required to deliver shares or make a cash payment to the counterparty.
Risks: The filing notes standard provisions for adjustments, acceleration, extension, or early termination by the counterparty.
Investor Verification Checklist
- Verify the exact number of shares initially delivered on November 4, 2024, based on the October 31 closing price.
- Monitor the volume-weighted average price of NBIX stock during the ASR term to estimate final share count.
- Confirm the remaining balance of the $300.00 million repurchase program after this transaction settles.
- Review the final settlement terms in the first quarter of 2025 for any cash adjustments or additional share deliveries.